Moss Genomics Announces Strategic Investment in Genomes.io
Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has entered into a non-binding term sheet for a strategic, non-controlling equity investment in Genomes.io Ltd. ("Genomes.io"), a UK-based company focused on secure, user-owned genomic data storage leveraging blockchain infrastructure.
Under the terms of the proposed investment, Moss would acquire a non-controlling equity interest in Genomes.io in exchange for 1,111,112 common shares of Moss, priced at $0.18 CAD per share (the "Moss Consideration Shares"). In connection with the investment, Moss will also receive the right to appoint one (1) board representative to the board of Genomes.io.
"This investment marks an exciting step forward in aligning our genomics platform with one of the most advanced privacy-first data infrastructures globally," said Jack Liu, CEO of Moss Genomics. "Genomes.io shares our vision of decentralization, transparency, and long-term patient data ownership — and we're thrilled to support their mission."
"We are very excited to be working with Moss Genomics and welcome them to our Board," said Aldo de Pape, Co-Founder and CEO of Genomes.io. "We are looking forward to growing our companies together, bringing safety, security, and scale to a sector that direly needs it."
Completion of the investment is subject to execution of definitive agreements and satisfaction of customary closing conditions, including applicable regulatory, Canadian Securities Exchange ("CSE") and corporate approvals. The Moss Consideration Shares to be issued in connection with the proposed investment is anticipated to be subject to a requisite hold period under the policies of the CSE and applicable securities laws.
The Company will issue further announcement(s) to update shareholders regarding material developments relating to the potential investment as and when necessary.
About Genomes.io
Founded in 2018 and based in London, Genomes.io operates a blockchain-secured DNA data vault that allows individuals to store, control, and selectively share their whole-genome sequences. Genomes.io's platform emphasizes privacy, data ownership, and transparency through the use of homomorphic encryption and blockchain auditing.
About Moss Genomics Inc.
Moss Genomics is a biotechnology company focused on genomics research to develop advanced genetic insights and solutions. Along with its genomics-focused products, Moss Genomics deploys a crypto accumulation strategy as part of its treasury management, currently holding 316 ETH on its balance sheet.